国家医保药品目录中儿童止咳平喘类中成药的组方规律OA

Objective:To analyze the compatibility patterns of pediatric cough-relieving and asthma-alleviating Chinese patent medicines listed in the Medicine List for National Basic Medical Insurance,Employment Injury Insurance and Maternity Insurance(2023 edition)(hereinafter referred to as"the National Reimbursement Drug List")based on data mining techniques.Methods:Pediatric-specific preparations in the National Reimbursement Drug List were screened.The medicinal efficacy,properties,flavors,and meridian tropisms were statistically analyzed.Association rule mining and cluster analysis were performed by using SPSS Modeler 18.0 and IBM SPSS 27.0.Results:Eighteen pediatric cough-relieving and asthma-alleviating Chinese patent medicines were enrolled,including 82 kinds of traditional Chinese medicines(180 times in total).High-frequency traditional Chinese medicines were respectively licorice(13 times),Amygdalus communis vas(12 times),Ephedra herba(10 times),and Gypsum fibrosum(10 times).Association rule analysis revealed that formulations were predominantly based on modification of Maxing Shigan decoction.Conclusion:Maxing Shigan decoction holds fundamental guiding significance for the formulation design of modern Chinese patent medicines targeting pediatric cough-relieving and asthma-alleviating.The mining results of core formulas have significant reference value for the screening of Chinese patent medicines prescriptions in medical institutions.